In_IN Vitro_NP Activities_NP of_IN Garenoxacin_NP (_( BMS-284756_NP )_) against_IN 170_CD Clinical_JJ Isolates_NNS of_IN Nine_NP Pasteurella_NP Species_NPS The_NP in_IN vitro_NN susceptibilities_NNS of_IN 170_CD clinical_JJ isolates_NNS plus_CC 12_CD American_NP Type_NP Culture_NP Collection_NP strains_NNS of_IN Pasteurella_NP species_NNS comprising_VBG nine_CD species_NNS and_CC three_CD Pasteurella_NP multocida_NN subspecies_NN were_VBD studied_VBN by_IN an_DT agar_NN dilution_NN method_NN ._SENT Garenoxacin_NP (_( BMS-284756_NP )_) ,_, a_DT new_JJ des-fluoro(6)_NN quinolone_NN ,_, was_VBD active_JJ at_IN <=0.06_mug/ml 90_CD %_NN of_IN the_DT strains_NNS susceptible_JJ to_TO <=0.008_JJ mug/ml_NN ._SENT Garenoxacin_NP was_VBD generally_RB 1_CD to_TO 2_CD dilutions_NNS more_RBR active_JJ than_IN levofloxacin_NN and_CC moxifloxacin_NN and_CC was_VBD the_DT most_RBS active_JJ agent_NN tested_VBD ._SENT Cefoxitin_NP required_VBD 1_CD mug/ml_NN for_IN inhibition_NN of_IN 51_CD of_IN 182_CD (_( 29_CD %_NN )_) of_IN strains_NNS ,_, and_CC 3_CD strains_NNS (_( also_RB beta-lactamase_NN producers_NNS )_) were_VBD resistant_JJ to_TO doxycycline_NN ._SENT Approximately_RB 245,000_CD to_TO 725,000_CD (_( 5_CD to_TO 15_CD %_NN of_IN the_DT 4.5_CD million_CD people_NNS who_WP suffer_VBP animal-bite_NN wounds_NNS in_IN the_DT United_NP States_NPS annually_RB seek_VBP medical_JJ attention_NN for_IN infection_NN ,_, including_VBG 30,000_CD patients_NNS who_WP visit_VBP an_DT emergency_NN department_NN for_IN medical_JJ treatment_NN and_CC 10,000_CD who_WP are_VBP hospitalized_VBN with_IN a_DT bite_NN wound_NN infection_NN ._SENT Bite_NN wound_VBD infections_NNS involve_VB a_DT complex_JJ polymicrobial_JJ flora_NN ,_, among_IN which_WDT Pasteurella_NP multocida_NP is_VBZ considered_VBN an_DT important_JJ pathogen_NN by_IN clinicians_NNS ._SENT Recent_JJ advances_NNS in_IN molecular_JJ methods_NNS have_VBP suggested_VBN a_DT more_RBR complex_JJ taxonomic_JJ structure_NN of_IN the_DT genus_NN Pasteurella_NP ,_, with_IN 11_CD genetically_RB closely_RB related_VBN taxa_NNS ,_, the_DT establishment_NN of_IN three_CD subspecies_NN of_IN P._NP multocida_NP ,_, and_CC a_DT reevaluation_NN of_IN 11_CD taxa_NNS with_IN low_JJ levels_NNS of_IN genetic_JJ relatedness_NN ._SENT Many_JJ of_IN the_DT genetically_RB closely_RB related_VBN species_NNS have_VBP different_JJ ecological_JJ niches_NNS ,_, different_JJ pathogenic_JJ potentials_NNS ,_, and_CC different_JJ propensities_NNS for_IN specific_JJ tissue_NN invasion_NN ._SENT A_DT recent_JJ prospective_JJ study_NN demonstrated_VBD that_IN Pasteurella_NP species_NNS are_VBP the_DT most_RBS common_JJ aerobic_JJ isolates_NNS from_IN both_DT dog_NN bites_NNS (_( 50_CD %_NN )_) and_CC cat_NN bites_NNS (_( 75_CD %_NN )_) ._SENT However_RB ,_, P._NP canis_NP is_VBZ the_DT predominant_JJ isolate_NN present_NN in_IN 26_CD %_NN of_IN dog-bite_NN wounds_NNS ,_, followed_VBN by_IN P._NP stomatis_NNS (_( 12_CD %_NN )_) and_CC P._NP multocida_NP subsp_NN ._SENT multocida_NP (_( 12_CD %_NN )_) ._SENT In_IN addition_NN ,_, P._NP dagmatis_NNS (_( 4_CD %_NN )_) and_CC P._NP multocida_NP subsp_NN ._SENT gallicida_NP (_( 2_CD %_NN )_) and_CC P._NP multocida_NP subsp_NN ._SENT septica_NP (_( 10_CD %_NN )_) are_VBP also_RB encountered_VBN in_IN dog-bite_NN wounds_NNS ._SENT In_IN contrast_NN ,_, P._NP multocida_NP subsp_NN ._SENT multocida_NP and_CC P._NP multocida_NP subsp_NN ._SENT septica_NNS are_VBP more_RBR prevalent_JJ in_IN cat-bite_NN wound_NN infections_NNS (_( present_JJ in_IN 54_CD and_CC 28_CD %_NN of_IN such_JJ wound_NN infections_NNS ,_, respectively_RB )_) ._SENT Most_JJS studies_NNS of_IN the_DT antimicrobial_JJ susceptibilities_NNS of_IN members_NNS of_IN the_DT family_NN Pasteurellaceae_NNS are_VBP often_RB limited_VBN because_IN veterinary_JJ and_CC human_JJ isolates_NNS are_VBP combined_VBN or_CC the_DT full_JJ spectrum_NN of_IN Pasteurella_NP species_NNS causing_VBG human_JJ infections_NNS is_VBZ not_RB tested_VBN ._SENT Pasteurella_NN species_NNS are_VBP associated_VBN with_IN a_DT variety_NN of_IN human_JJ infections_NNS ,_, most_JJS but_CC not_RB all_DT of_IN which_WDT are_VBP associated_VBN with_IN animal_JJ contact_NN ,_, especially_RB dog_NN and_CC cat_NN bites_NNS ._SENT While_IN many_JJ patients_NNS with_IN bite_NN wounds_NNS receive_VBP a_DT beta-lactam_NN agent_NN such_JJ as_IN amoxicillin-clavulanate_NN ,_, approximately_RB 20_CD %_NN will_MD report_VB a_DT history_NN of_IN an_DT adverse_JJ reaction_NN to_TO penicillin_NN or_CC other_JJ beta-lactam_NN antibiotics_NNS and_CC require_VB an_DT appropriate_JJ alternative_NN agent_NN ._SENT Fluoroquinolones_NNS have_VBP been_VBN suggested_VBN as_IN alternative_JJ agents_NNS for_IN the_DT treatment_NN of_IN bite_NN wounds_NNS ._SENT Garenoxacin_NP {_( BMS-284756_NP ;_: T-3811ME_NP ;_: 1-cyclopro-pyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-5-isoindolyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic_JJ acid_JJ methanesulfonate_NN monohydrate_NN }_) is_VBZ a_DT new_JJ des-fluoro(6)_NN quinolone_NN that_WDT lacks_VBZ the_DT 6-position_JJ fluorine_NN that_WDT characterizes_VBZ the_DT previous_JJ class_NN of_IN fluoroquinolones_NNS ._SENT Preliminary_JJ data_NNS indicate_VBP that_IN this_DT drug_NN has_VBZ a_DT broad_JJ spectrum_NN of_IN activity_NN against_IN most_JJS gram-positive_JJ and_CC gram-negative_JJ aerobes_NNS including_VBG certain_JJ strains_NNS that_WDT are_VBP resistant_JJ to_TO other_JJ fluoroquinolones_NNS ._SENT We_PP therefore_RB studied_VBD the_DT antimicrobial_JJ susceptibilities_NNS of_IN 170_CD clinical_JJ isolates_NNS and_CC 12_CD American_NP Type_NP Culture_NP Collection_NP (_( ATCC_NP )_) strains_NNS of_IN the_DT family_NN Pasteurellaceae_NP consisting_VBG of_IN the_DT nine_CD species_NNS and_CC three_CD P._NP multocida_NP subspecies_NN most_RBS often_RB associated_VBN with_IN human_JJ infections_NNS ._SENT Almost_RB all_RB of_IN the_DT strains_NNS had_VBD previously_RB been_VBN isolated_VBN from_IN bite_NN wounds_NNS (_( almost_RB all_RB of_IN the_DT strains_NNS were_VBD isolated_VBN from_IN 1995_CD to_TO 2002_CD )_) and_CC were_VBD identified_VBN according_VBG to_TO standard_JJ criteria_NNS ._SENT The_DT sources_NNS of_IN the_DT isolates_NNS were_VBD as_RB follows_VBZ :_: dog_NN bites_NNS ,_, 60_CD strains_NNS ;_: cat_NN bites_NNS ,_, 81_CD strains_NNS ;_: tiger_NN bites_NNS ,_, 2_CD strains_NNS ;_: bites_NNS caused_VBN by_IN other_JJ animals_NNS ,_, 15_CD strains_NNS ;_: and_CC bovine_JJ respiratory_JJ sources_NNS ,_, 12_CD strains_NNS ._SENT The_DT three_CD isolates_NNS of_IN P._NP caballi_NP and_CC six_CD of_IN the_DT eight_CD strains_NNS of_IN P._NP haemolytica_NP were_VBD from_IN bovine_JJ respiratory_JJ sources_NNS ._SENT For_IN comparative_JJ purposes_NNS ,_, 12_CD ATCC_NP strains_NNS of_IN 10_CD species_NNS (_( P._NP aerogenes_NNS ATCC_NP 12192_CD ,_, P._NP canis_NP ATCC_NP 43326_CD ,_, P._NP dagmatis_NN ATCC_NP 43325_CD ,_, P._NP haemolytica_NP ATCC_NP 33396_CD ,_, P._NP multocida_NP subsp_NN ._SENT gallicida_NP ATCC_NP 51689_CD and_CC ATCC_NP 51696_CD ,_, P._NP multocida_NP subsp_NN ._SENT multocida_NP ATCC_NP 7228_CD and_CC ATCC_NP 12947_CD ,_, P._NP multocida_NP subsp_NN ._SENT septica_NP ATCC_NP 51688_CD ,_, P._NP pneumotropica_NP ATCC_NP 35149_CD ,_, P._NP stomatis_NN ATCC_NP 43327_CD ,_, and_CC P._NP testudinis_NP ATCC_NP 3368_CD )_) were_VBD also_RB tested_VBN ._SENT Standard_JJ laboratory_NN powders_NNS were_VBD supplied_VBN ,_, as_RB follows_VBZ :_: garenoxacin_NN ,_, Bristol-Myers_NP Squibb_NP Co._NP ,_, Princeton_NP ,_, N.J._NP ;_: amoxicillin-clavulanate_NN ,_, SmithKline_NP Beecham_NP Pharmaceuticals_NPS ,_, Philadelphia_NP ,_, Pa._NP ;_: ampicillin-sulbactam_NP ,_, Pfizer_NP Inc._NP ,_, New_NP York_NP ,_, N.Y._NP ;_: levofloxacin_NP ,_, Ortho-McNeil_NP Pharmaceuticals_NPS ,_, Raritan_NP ,_, N.J._NP ;_: moxifloxacin_NP ,_, Bayer_NP Corp._NP ,_, West_NP Haven_NP ,_, Conn._NP ;_: cefoxitin_NN ,_, Merck_NP &_CC Co._NP ,_, West_NP Point_NP ,_, Pa._NP ;_: and_CC doxycycline_NN and_CC penicillin_NN G_NN ,_, Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, Mo._NP Antimicrobial_JJ agents_NNS were_VBD reconstituted_VBN according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturers_NNS ._SENT Serial_JJ twofold_JJ dilutions_NNS were_VBD added_VBN to_TO the_DT media_NNS on_IN the_DT day_NN of_IN testing_NN ._SENT Frozen_JJ cultures_NNS were_VBD transferred_VBN twice_RB to_TO ensure_VB purity_NN and_CC good_JJ growth_NN ._SENT Susceptibility_NN testing_NN was_VBD performed_VBN according_VBG to_TO NCCLS_NP standards_NNS ._SENT The_DT basal_JJ medium_NN used_VBN was_VBD Mueller-Hinton_NP agar_NN supplemented_VBD with_IN 5_CD %_NN sheep_NN blood_NN ._SENT The_DT agar_NN plates_NNS were_VBD inoculated_VBN with_IN a_DT Steers_NP replicator_NN (_( Craft_NP Machine_NP Inc._NP ,_, Chester_NP ,_, Pa._NP )_) with_IN an_DT inoculum_NN of_IN 104_CD CFU_NN per_IN spot_NN ._SENT Control_NN plates_NNS without_IN antimicrobial_JJ agents_NNS were_VBD inoculated_VBN before_IN and_CC after_IN the_DT inoculation_NN of_IN each_DT set_NN of_IN drug-containing_VBG plates_NNS ._SENT Escherichia_NP coli_NNS ATCC_NP 25922_CD and_CC Staphylococcus_NP aureus_NN ATCC_NP 29213_CD were_VBD included_VBN as_IN controls_NNS ._SENT Plates_NNS were_VBD incubated_VBN at_IN 35C_JJ in_IN an_DT aerobic_JJ environment_NN for_IN 18_CD to_TO 20_CD h_NN and_CC were_VBD then_RB examined_VBN ;_: the_DT MIC_NN was_VBD defined_VBN as_IN the_DT lowest_JJS concentration_NN of_IN an_DT agent_NN that_WDT yielded_VBD no_DT growth_NN or_CC a_DT marked_JJ change_NN in_IN growth_NN compared_VBN to_TO the_DT growth_NN on_IN the_DT control_NN plate_NN ._SENT The_DT results_NNS of_IN the_DT present_JJ study_NN ,_, in_IN which_WDT we_PP tested_VBD a_DT large_JJ number_NN of_IN clinical_JJ isolates_NNS of_IN nine_CD Pasteurella_NP species_NNS ,_, including_VBG the_DT three_CD P._NP multocida_NN subspecies_NN ,_, are_VBP presented_VBN in_IN Table_NP ._SENT Garenoxacin_NP was_VBD active_JJ at_IN <0.06_mug/ml 90_CD %_NN of_IN the_DT strains_NNS susceptible_JJ to_TO <0.008_JJ mug/ml_NN ._SENT Three_CD of_IN these_DT four_CD strains_NNS ,_, including_VBG the_DT two_CD strains_NNS of_IN P._NP haemolytica_NP and_CC the_DT single_JJ strain_NN of_IN P._NP aerogenes_NNS ,_, were_VBD also_RB resistant_JJ to_TO doxycycline_NN ._SENT Cefoxitin_NP required_VBD 1_CD to_TO 2_CD mug/ml_NN for_IN inhibition_NN of_IN 51_CD of_IN 182_CD (_( 29_CD %_NN )_) strains_NNS ._SENT Garenoxacin_NP was_VBD generally_RB 1_CD to_TO 2_CD dilutions_NNS more_RBR active_JJ than_IN levofloxacin_NN and_CC moxifloxacin_NN on_IN a_DT weight_NN basis_NN and_CC was_VBD the_DT most_RBS active_JJ agent_NN tested_VBD ._SENT TABLE_NN 1_CD |_SYM Comparative_JJ in_IN vitro_NN activities_NNS of_IN the_DT des-quinolone_JJ garenoxacin_NN (_( BMS-284756_NP )_) and_CC seven_CD other_JJ agents_NNS against_IN 182_CD clinical_JJ isolates_NNS of_IN Pasteurella_NP species_NNS Pasteurella_NP species_NNS are_VBP normal_JJ inhabitants_NNS of_IN 12_CD to_TO 92_CD %_NN of_IN dogs_NNS and_CC 52_CD to_TO 99_CD %_NN of_IN cats_NNS ,_, and_CC most_RBS human_JJ infections_NNS are_VBP associated_VBN with_IN bites_NNS or_CC animal_NN exposure_NN ._SENT Many_JJ publications_NNS do_VBP not_RB differentiate_VB or_CC identify_VB the_DT different_JJ Pasteurella_NP species_NNS ,_, sometimes_RB due_JJ to_TO technical_JJ difficulties_NNS with_IN the_DT interpretation_NN of_IN biochemical_JJ tests_NNS ._SENT Our_PP$ laboratory_NN has_VBZ recently_RB reported_VBN on_IN the_DT use_NN of_IN PCR_NP fingerprinting_VBG and_CC alpha-glucosidase_NN activity_NN as_IN a_DT means_NN of_IN differentiating_VBG P._NP multocida_NP subsp_NN ._SENT multocida_NN from_IN P._NP multocida_NP subsp_NN ._SENT septica_NN ._SENT Some_DT investigators_NNS have_VBP suggested_VBN different_JJ pathogenic_JJ potentials_NNS and_CC ecological_JJ niches_NNS for_IN the_DT different_JJ species_NN ,_, which_WDT increases_VBZ the_DT clinical_JJ importance_NN of_IN differentiating_VBG these_DT species_NN in_IN reports_NNS of_IN studies_NNS ._SENT For_IN example_NN ,_, P._NP multocida_NP subsp_NN ._SENT multocida_NP and_CC P._NP multocida_NP subsp_NN ._SENT septica_NNS are_VBP more_RBR frequently_RB recovered_VBN from_IN "_`` more_RBR serious_JJ "_'' infections_NNS ,_, including_VBG bacteremias_NNS ,_, and_CC P._NP multocida_NP subsp_NN ._SENT septica_NN is_VBZ more_RBR frequently_RB isolated_VBN from_IN cat-bite_NN wounds_NNS and_CC has_VBZ an_DT affinity_NN for_IN the_DT central_JJ nervous_JJ system_NN ._SENT In_IN a_DT prior_JJ study_NN from_IN our_PP$ laboratory_NN ,_, in_IN which_WDT the_DT same_JJ methodology_NN described_VBD here_RB but_CC a_DT limited_JJ number_NN of_IN isolates_NNS was_VBD used_VBN ,_, we_PP found_VBD that_IN all_DT Pasteurella_NP multocida_NN subsp_NN ._SENT multocida_NP and_CC P._NP multocida_NP subsp_NN ._SENT septica_NN isolates_NNS were_VBD susceptible_JJ to_TO <=0.015_JJ mug_NN of_IN garenoxacin_NN per_IN ml_NN ._SENT In_IN general_NN ,_, the_DT quinolones_NNS ,_, including_VBG gatifloxacin_NN ,_, moxifloxacin_NP ,_, trovafloxacin_NN ,_, and_CC levofloxacin_NN ,_, have_VBP consistently_RB been_VBN active_JJ against_IN P._NP multocida_NP and_CC other_JJ Pasteurella_NP species_NNS ._SENT On_IN the_DT basis_NN of_IN our_PP$ in_IN vitro_NN data_NNS ,_, garenoxacin_NN offers_VBZ an_DT alternative_NN for_IN the_DT treatment_NN of_IN human_JJ infections_NNS associated_VBN with_IN all_DT Pasteurella_NP species_NN ._SENT 